Company Overview and News
2018-08-10 zacks - 1
Abeona Therapeutics (ABEO - Free Report) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to loss of $0.21 per share a year ago. These figures are adjusted for non-recurring items.
GD UNIT ABEO ABEOW
NEW YORK and CLEVELAND, Aug. 09, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies for life-threatening rare genetic diseases, today announced financial results for the second quarter of 2018. The Company will host a call to update investors on recent clinical developments and quarter financial results on Friday, August 10th at 10:00 am (Eastern).
2018-08-06 biospace - 2
Cellectis – France-based Cellectis named Novartis veteran Stefan Scherto as its new head of clinical development and deputy medical officer. Prior to his role at Cellectis, Scherto served as head of early development of strategy and innovation in U.S. oncology for Novartis. Scherto is expected to play a key role in moving Cellectis’ off-the-shelf gene-edited CAR-T cell product candidates toward commercialization.
ABT ALXN GILD TRVN QSII KITE ABEO ABEOW ABT BCART
Nabriva Therapeutics – Nabriva Therapeutics restructured part of its leadership team in the wake of the acquisition of Zavante Therapeutics. Colin Broom, who had served as chief executive officer of Nabriva, was replaced by Zavante CEO Ted Schroeder. Broom will maintain a seat on the board of directors and serve in an advisory role to Schroeder. Steven Gelone, Nabriva's chief scientific officer and head of business & corporate development, has been named president and chief operating officer of Nabriva.
VYGR OPTI ALXN NBRV ABEO ABEOW ARIA OPBXF
There are clear risks in terms of continued dilution, but we believe these risks are outweighed by the positive data presented from Fibrocell's lead gene therapy program, FCX-007.
FCSC KRYS ABEO ABEOW
2018-07-13 seekingalpha - 3
The overall bioscience market traded with a mixed sentiment for the day. Nevertheless, many equities under over coverage continued to rally.
NTLA SLDB SGMO CRSP ABEO XBI ONCE RGNX NEPH EDIT ADVM IBB ABEOW
Synacor, Inc. (SYNC - Free Report) has been struggling lately, but the selling pressure may be coming to an end soon. That is because SYNC recently saw a Hammer Chart Pattern which can signal that the stock is nearing a bottom.
LMT SYNC ABEO ABEOW
Old Dominion Freight Line, Inc. (ODFL - Free Report) has been struggling lately, but the selling pressure may be coming to an end soon. That is because ODFL recently saw a Hammer Chart Pattern which can signal that the stock is nearing a bottom.
ODFL LMT ABEO ABEOW ODLF
GMS Inc. (GMS - Free Report) has been struggling lately, but the selling pressure may be coming to an end soon. That is because GMS recently saw a Hammer Chart Pattern which can signal that the stock is nearing a bottom.
LMT ABEO ABEOW GMS
2018-07-12 zacks - 1
Pacific Ethanol, Inc. (PEIX - Free Report) has been struggling lately, but the selling pressure may be coming to an end soon. That is because PEIX recently saw a Hammer Chart Pattern which can signal that the stock is nearing a bottom.
LMT PEIX ABEO ABEOW
Investors in Abeona Therapeutics Inc. (ABEO - Free Report) need to pay close attention to the stock based on moves in the options market lately. That is because the Jul 20, 2018 $17.50 Call had some of the highest implied volatility of all equity options today.
2018-06-21 fintel.io - 1
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) has 53 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 15,564,771 shares. Largest shareholders include New Leaf Venture Partners, L.L.C., Viking Global Investors LP, SV Life Sciences Advisers, LLC, Orbimed Advisors Llc, FMR LLC / Fidelity, Redmile Group, LLC, BlackRock Inc.
DCPH PRTO BLK IOVA GALPW ABEO ABEOW GALE MEIP GALEW
2018-06-18 seekingalpha - 1
If cell therapies are curative, new business models will become more cyclical. Harvoni and Sovaldi cure rates exceeding 90% show Gilead understands this new paradigm.
VYGR BOLD NTLA ATRA EDIT GILD CRSP ABEO ABEOW ONCE
2018-08-20 - Asif
Overview Recro Pharma is a specialty pharmaceutical company that operates through two business divisions: an Acute Care division and a revenue-generating CDMO division. Each of these divisions are deemed to be reportable segments for financial reporting purposes. The company's Acute Care segment is primarily focused on developing and commercializing innovative products for hospital and related acute care settings. The company's lead product candidate is a proprietary injectable form of meloxicam, a long-acting preferential COX-2 inhibitor. IV meloxicam has successfully completed three Phase III clinical trials for the management of moderate to severe pain, consisting of two pivotal efficacy trials and a large double-blind Phase III safety trial, as well as other safety studies. Overall, the total new drug application, or NDA, program included over 1,400 patients. In late July 2017, the company submitted a NDA to the U.S. Food and Drug Administration, or FDA, for IV meloxicam...
2018-08-20 - Asif
Overview Achillion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on advancing its oral factor D inhibitors into late-stage development and commercialization. Each of the drug candidates in its oral factor D portfolio was discovered in its laboratories and is wholly owned by it. Achillion Pharmaceuticals is focusing its drug development activities on alternative pathway-mediated, rare diseases where there are no approved therapies or where existing therapies are inadequate for patients. To advance its investigational drugs into phase III and commercialization, the company plan to work closely with key stakeholders including patients, payors, regulators and healthcare professionals. The company's first-generation factor D inhibitor, ACH-4471, has demonstrated preliminary clinical proof-of-concept in patients with C3 glomerulopathy, or C3G, a disease affecting the kidney, and paroxysmal nocturnal hemoglobinuria, or PNH, a blood disorder, and has advanced...
2018-08-20 - Asif
General Baytex Energy Corp. was incorporated on October 22, 2010 pursuant to the provisions of the ABCA. Baytex is the successor to the business of Baytex Energy Trust, which was transitioned to Baytex on December 31, 2010. Inter-Corporate Relationships The following table provides the name, the percentage of voting securities owned by it and the jurisdiction of incorporation, continuance, formation or organization of its material subsidiaries either, direct and indirect, as at the date hereof. ||Percentage of voting securities (directly or indirectly)|Jurisdiction of Incorporation/Formation| | ------------ | ------------: | :------------: | |Baytex Energy Ltd.|100%|Alberta| |Baytex Energy USA, Inc.|100%|Delaware| |Baytex Energy Partnership|100%|Alberta| Organizational Structure The following simplified diagram shows the inter-corporate relationships among it and its material subsidiaries as of the date hereof. <img src="https://www.sec.gov/A...
as of ET